- Advertisement -spot_img
Tuesday, May 24, 2022

Vaccination of the world with CV-19

Editor’s Note Catch: Find the latest CV-19 news and instructions at Medscape’s Coronavirus Resource Center.

Since the advent of vaccines in late 2020, more than half of the world’s population has been vaccinated against covide-19, a scientific breakthrough. People in low-income countries will get even one dose by the end of March 2022.

One of the reasons for this disparity is that the most successful MRI vaccines in developed countries are new, expensive, and technologically challenging. Only a handful of companies are capable of producing them, and high-income countries stock up on more than 70 percent of the drug.

Efforts are underway to increase the production of MRI vaccines in middle- and low-income countries, including some African countries. However, MRI is weak and difficult to handle, and requires some vaccines to be stored at very cold temperatures. This increases the complexity of vaccine production and the challenges of its distribution in remote areas. Vaccines that use genetically modified viruses to promote coronavirus proteins such as the Johnson & Johnson vaccine are also relatively new and technically challenging.

According to Maria Elena Botazi, a researcher at the University of Houston Medical College in Vaccine, the best option is to switch to traditional immunization technologies that do not require much new infrastructure. Botazi plans to launch CVD-19 vaccines in 2022 using more accessible technologies. Annual Medical Review. Such vaccines are more than 90% effective in stimulating the immune system to produce antibodies and, like mRNA vaccines, by delivering complete, inactivated viruses or viral protein debris.

As with mRNA technology, factories already include hepatitis A and B and polio vaccines, which are known to produce these older types of vaccines in many middle- and low-income countries. Such immunizations cost less than the new MRI vaccines, a few dollars per dose, more than $ 10 per dose. In collaboration with the Indian company Biological E, Botazi and Belarus’ partner and collaborator Peter Hotez have authorized the use of the protein debris to use the Corbevax vaccine, now in India and Botswana.

A popular magazine He discussed with Bottazzi some of the challenges that make the vaccine universal and some of the barriers to vaccination. This conversation has been modified for a long time and transparency.

What is a “good” vaccine for international use?

You need to have strong technology suitable for the region, which includes expansion, storage conditions, product characteristics. You need to have the right infrastructure to make, deliver and control vaccines. And you have to have all the tools you need to make them. We cannot have a single source, because after that countries will stop exporting, as we have seen US-made reagents or India-made vaccines.

Why are MRI vaccines developed by Pfizer and Moderna not a universal solution?

We could not do enough. There were not enough production facilities to do this – it was impossible. So, they would only resort to this as a last resort. We could not distribute it evenly. And of course, some countries have benefited more than others, because there is purchasing power. If you can afford them, stock up on supplies.

Is there a better alternative?

Protein-based vaccines are ideal for becoming a global vaccine. They do not have to start from scratch, so you already have the expertise and expertise in creating them. And they are easy to work with, so you have a balanced economy.

But I think the most important characteristic is social. It really depends on the acceptance of these products. The vaccine should instill confidence in the user. People are afraid – not only because they are in the middle of an epidemic, but also because of all these new tools. Some people are obviously early guardians, but there are many of us who prefer to wait a little longer and see what happens.

To some extent, people are more confident when they know it is the same vaccine they have been using for many years. That’s why a vaccine like the one we made can help. People are well aware of the fact that protein-based vaccines have been used in the past. “When will your Corbevax vaccine come to the United States? This is the vaccine I was expecting because I have used this vaccine before. This is happening not only here, but all over the world.

And how they establish clinical safety and effectiveness. We want to include more people. I think we have that issue with Covid now. We need more research in countries like Honduras, Ethiopia and Thailand.

Even with known vaccine technologies, it takes a lot of work to develop a new vaccine. He argued that this should be done worldwide, locally and regionally, rather than relying on a few nations. Doesn’t this lead to repeated efforts?

They think it is too much, but it clearly shows us that covid producers and supply chains are very integrated in very few regions. When you urgently need to address a situation, those producers will not be able to access the small, often high-income areas, and rich countries may raise prices or nationalize the vaccine. We are not saying that you have to renew the wheel everywhere – but in a systematic way, regions have to be able to make themselves more equitable.

How does your vaccine, which is being developed by an Indian company Biological E, help to achieve this?

We gave the recipe to Bioi but in the end they needed to develop the vaccine themselves. They needed to know how to work in an industrial way. They had to be new creators, and now they can teach others to do it, so everyone can do their own thing. That is very different, because it does not come from the traditional plural model of “I deliver and do as I tell you.” They are promoting and facilitating indigenous production and innovation.

How do some countries respond to concerns that they may lack technical knowledge to produce high-quality vaccines, or regulatory scrutiny to assess them?

I do not completely agree that these producers, especially the producers of middle-income countries, are in a lower category compared to international companies. They already produce many vaccines. He has previously undergone clinical evaluations by several regulatory agencies. In places like Indonesia and India, there are quality control agencies that have complied with international standards for years. They have already proven themselves.

BioI is working to obtain a license from the World Health Organization. They are working with the Australian Regulatory Agency because Indian regulators are one of the strictest regulatory agencies in the world. I think it is a lie to say that the vaccines are different from those produced in the US or Europe just because they are produced in India.

Why are CVD vaccines only available now that use old and well-known technologies? What makes them so slow to grow?

It is not slow. we had [protein-based vaccine] Three months before the outbreak, technology is ready. And we delivered it to Biological E in May 2020.

BioE has struggled to develop it. They did it as fast as they could – not because they did not have the financial support but because they did not have the support of the government or the political will. Governments have said they do not want you – we will connect with our new technologies, so we will not give you the money. They are now realizing that they have made a mistake. Now they say, “We want you.”

You have made patent technology available to all. Should all manufacturers do this?

There are some technologies, such as RNA technologies, why they want to prevent it from being logically new, because they are developing it for many other treatments. You can be more careful when you open it.

We could have patent protection, but we decided not to. We do not want obstacles. Basically, “Look, you want to try our strategy, you can do it yourself, because it’s all published. But we really want to work with you if you need help.

Covide-19 will not be the last epidemic. Are there lessons to be learned next time?

I think we need to encourage countries, especially low-income countries – not only in terms of technology but also in terms of how well they create public health systems. We need to empower them to be more self-sufficient so that they can build a strong workforce and not be discouraged, but then hold them accountable for creating their own infrastructure to build that region or country. All countries should never be independent but should be mutually supportive. Our vision is to work together in good times and bad. But this has to do with political will.

Why should people in developed countries worry about global vaccination equity? There is an obvious humanitarian debate – but is there a real reason to invest in dollars or doses elsewhere to vaccinate people?

We are a large community. Elsewhere, we are not immune to the ill effects of a major disease. We see it in Kovid. It is clear that the differences stem from our lack of access to other regions’ equitable access to essential equipment such as vaccines, medicines and tests. Helping others means helping ourselves.

This article first appeared in the April 18, 2022, issue of Awake! A well-known magazine is a journalistic effort independent of annual reviews, a non-profit publisher for the advancement of science and the integration of knowledge for the benefit of society. Subscribe to a popular magazine.


World Nation News Deskhttps://www.worldnationnews.com
World Nation News is a digital news portal website. Which provides important and latest breaking news updates to our audience in an effective and efficient ways, like world’s top stories, entertainment, sports, technology and much more news.
Latest news
Related news
- Advertisement -


Please enter your comment!
Please enter your name here